Published in

BMJ Publishing Group, Heart, 23(95), p. 1920-1924

DOI: 10.1136/hrt.2009.173344

Elsevier, Year Book of Endocrinology, (2010), p. 284-286

DOI: 10.1016/s0084-3741(10)79570-6

Elsevier, Year Book of Medicine, (2010), p. 484-486

DOI: 10.1016/s0084-3873(10)79815-1

Links

Tools

Export citation

Search in Google Scholar

Aldosterone status associated with insulin resistance in patients with heart failure-data from the ALOFT study

This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

Background: Aldosterone has a key role in the pathophysiology of heart failure. In around 50% of such patients, aldosterone "escapes'' from inhibition by drugs that interrupt the renin-angiotensin axis; such patients have a worse clinical outcome. Insulin resistance is a risk factor in heart failure and cardiovascular disease. The relation between aldosterone status and insulin sensitivity was investigated in a cohort of heart failure patients. Methods: 302 patients with New York Heart Association (NYHA) class II-IV heart failure on conventional therapy were randomised in the ALiskiren Observation of heart Failure Treatment study (ALOFT), designed to test the safety of a directly acting renin inhibitor. Plasma aldosterone and 24-hour urinary aldosterone excretion, as well as fasting insulin and homeostasis model assessment of insulin resistance (HOMA-IR) were measured. Subjects with aldosterone escape and high urinary aldosterone were identified according to previously accepted definitions. Results: 20% of subjects demonstrated aldosterone escape and 34% had high urinary aldosterone levels. At baseline, there was a positive correlation between fasting insulin and plasma (r = 0.22 p